title: [The anti-inflammatory effect of 0.1% bromfenac and 0.1% betamethasone combination in post-cataract surgery patients with diabetes mellitus].
abstract: OBJECTIVE
  To compare the post cataract surgery anti-inflammatory effect of bromfenac monotherapy and of bromfenac and betamethasone combination therapy in diabetes mellitus patients.
  
  
  METHODS
  A prospective study approved by the Institutional Review Board. Fifty-one eyes of 51 patients were randomly allocated to either bromfenac 0.1% monotherapy (n = 23) or combined therapy with bromfenac 0.1% and betamethasone 0.1% (n = 28). After surgery, monotherapy group was administered bromfenac alone for 8 weeks, while the combined therapy group was administered both bromfenac and betamethasone for 2 weeks, bromfenac alone for the next 6 weeks. The amount of change from preoperative values in anterior chamber flare and foveal thickness were compared between the 2 groups.
  
  
  RESULTS
  There was no significant difference in change in anterior chamber flare between the 2 groups. The increase in foveal thickness 4 weeks postoperatively was significantly larger in the bromfenac group (p = 0.0356). Four patients of the bromfenac group, all with a history of diabetic macular edema, developed macular edema after surgery.
  
  
  CONCLUSIONS
  Bromfenac and betamethasone combination exhibited a stronger anti-inflammatory effect after cataract surgery patients with diabetes mellitus. In particular, patients with a history of diabetic macular edema were susceptible to foveal thickening and macular edema, and a combined treatment is desirable.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Terada
authors.forename: Ayami
authors.initials: A
authors.lastname: Masuda
authors.forename: Ryohei
authors.initials: R
authors.lastname: Nejima
authors.forename: Yoko
authors.initials: Y
authors.lastname: Maruyama
authors.forename: Kazunori
authors.initials: K
authors.lastname: Miyata
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use*; D001969:Bromobenzenes / Q000627:therapeutic use*; D002386:Cataract; D002387:Cataract Extraction / Q000379:methods; D048909:Diabetes Complications; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*
chemical_list: D000893:Anti-Inflammatory Agents; D001577:Benzophenones; D001969:Bromobenzenes; C053083:bromfenac; D001623:Betamethasone